As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could become the first disease-modifying ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with epidermolysis bullosa simplex treated with ...

Please provide your email address to receive an email when new articles are posted on . Castle Creek Pharmaceuticals announced it has enrolled the first patient in its phase 2/3 clinical trial to ...

BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, randomized, double-blind, ...

A previous Phase 2 trial of 17 patients with EBS showed that 60% of those treated with diacerein cream experienced at least a 40% reduction in blistering after 4 weeks vs 18% on vehicle. The Food and ...

In the present study, we analyzed a large, non-consanguineous five-generation family residing in Gujarat, India (Figure 1d). Blood samples were obtained, after informed consent, from a total of 14 ...

The Epidermolysis Bullosa market growth is driven by factors like increase in the prevalence of Epidermolysis Bullosa, investments in research and development, entry of emerging therapies during the ...

The Food and Drug Administration (FDA) has approved a transformational treatment for one of the most tragic of pediatric skin diseases. The first-of-its kind topical gene therapy for Epidermolysis ...

Epidermolysis bullosa (EB) is a group of rare inherited diseases affecting the connective tissue and is responsible for the resulting blisters that appear on the skin. These blisters are a consequence ...

The Dowling-Meara variant of epidermolysis bullosa simplex (EBS-DM) is a severe blistering disease inherited in an autosomal-dominant fashion. Here we report the generation of a mouse model that ...